Clinical trials: Cognitive Deficits, Mild
Alzheimer Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Trial name
- NCT04602624
- Testing
- SAGE-718
- Where
- 10 sites in United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Type 2 Diabetes, Mild Cognitive Impairment
Improving Medication Adherence in Older African Americans With Diabetes
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes.
- Trial name
- NCT02174562
- Testing
- Primary Care-Occupational Therapy, Enhanced Usual Care
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Thomas Jefferson University
Age-associated Cognitive Impairment, Mild Cognitive Impairment (MCI)
18-Month Study of Memory Effects of Curcumin
This project is designed to study the effects of the dietary supplement curcumin on age-related cognitive impairment. In particular, the study seeks to determine the effects of curcumin on cognitive decline and the amount of…
- Trial name
- Curcumin (NCT01383161)
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of California, Los Angeles
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Mild Cognitive Impairment
Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)
Nearly 1 in 10 older Americans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status.
- Trial name
- MCI PLIE (NCT03526146)
- Testing
- Behavioral: Preventing Loss of Independence through Exercise (PLIE)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Cognitive Dysfunction
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT03721705
- Testing
- Renew NCP-5
- Where
- 12 sites in United States, Ireland and 1 more
- Volunteers
- 190 people
- Sponsor
- Renew Research, LLC
Mild Cognitive Impairment, Alzheimer's Disease
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Remembering how to travel from one location to another is critical in everyday life, yet this vital ability declines with normal aging and can be further affected by conditions that disproportionately affect the elderly, such as…
- Trial name
- NCT01958437
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment
ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment
The Advance Care Planning Group Visit intervention is a new intervention that uses the strengths of group visits to promote advance care planning conversations and documentation.
- Trial name
- ENACT-aMCI (NCT03711396)
- Testing
- Advance Care Planning Group Visits
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Adherence, Treatment, Retention
KNA Proof-of-Concept
The intervention program proof-of-concept was assessed as a single-arm, within-subjects clinical study with a target enrollment of 10 participants with possible or probable amnestic MCI.
- Conditions
- Adherence, Treatment, Retention, Cognitive Impairment, Mild
- Trial name
- NCT04968041
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida State University
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Cognition Disorders in Old Age, Mild Cognitive Impairment
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline…
- Conditions
- Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT04078178
- Testing
- Niagen
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Steven E Arnold, MD
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Mild Cognitive Impairment
VR-CogMoBal Training for Reducing Falls Among Older Adults With Mild Cognitive Impairment
Older adults often display gait instability, impaired balance control and cognitive decline that lead to falls and fall risks. Approximately 60% of the elderly people with cognitive deficits experience a detrimental fall each…
- Trial name
- NCT03765398
- Testing
- VR Cognitive-motor-balance training
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Illinois Chicago
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Mild Cognitive Impairment (MCI)
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease…
- Trial name
- NCT01044758
- Testing
- Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment
Effects Multimodal Mind and Body Approach for MCI
The aim of this application is to develop a computer-based multimodal mind and body approach (CMMBA) for mild cognitive impairment (MCI).
- Trial name
- NCT06814483
- Testing
- Experimental: A computer-based multimodal mind and body approach (cbMMBA), A standard cognitive training group
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Subjective Memory Loss in Older Persons
Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints
The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels of substances in the blood that may be associated with thinking ability and the health of brain cells in subjects with memory concerns…
- Trial name
- NCT00597376
- Testing
- Cerefolin NAC (a medical food)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Rush University Medical Center
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.